Key facts
- This page summarizes Thomas J. Schuetz's Form 4 filing for Compass Therapeutics, Inc. (CMPX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 10 Feb 2026, 08:00.
Thomas J. Schuetz - 08 Feb 2026 Form 4 Insider Report for Compass Therapeutics, Inc. (CMPX)
- Reporting relationship
- CHIEF EXECUTIVE OFFICER, Director
- Issuer ticker
- CMPX
- Reported as of
- 08 Feb 2026
- Net transaction value
- -$239,199
- SEC form
- 4
- Accepted by SEC
- 10 Feb 2026, 08:00:15 UTC
- Prior SEC filing
- 12 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas J. Schuetz
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Thomas J. Schuetz filed Form 4 for Compass Therapeutics, Inc. (CMPX) on 10 Feb 2026.
Change
- Previous filing in this sequence was filed on 12 Jan 2026.
- Current net transaction value: -$239,199.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001591464
Primary reporting owner
Schuetz Thomas J.
- Relationship
- CHIEF EXECUTIVE OFFICER, Director
- Address
- C/O COMPASS THERAPEUTICS, INC., 80 GUEST ST., SUITE 601, BOSTON
- Signature
- /s/ Thomas J. Schuetz
- Signature date
- 10 Feb 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CMPX
transaction
Common Stock
Tax liability
- Transaction value
- $239,199
- Shares
- -36,687
- Change %
- -0.55%
- Price
- $6.52
- Shares after
- 6,603,336
- Date
- 08 Feb 2026
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").
Footnote F2
125,000 of the shares represent unvested restricted stock units ("RSU") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 318,750 of the shares represent unvested restricted stock units ("RSU") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025. 250,000 of the shares represent unvested restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027.